Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Imutec receives patent protection for Virulizin in Canada

Aug. 24, 1998

Available from NIH: immunotoxin for the treatment of ovarian cancer and mesotheliomas

Aug. 20, 1998

BLP25 cancer vaccine enters phase I testing in patients with NSCLC

Aug. 19, 1998

Canadian patent covers Jenner's cancer vaccine

Aug. 13, 1998

Avax to begin pivotal trial with M-Vax in melanoma patients

July 31, 1998

MabThera now available for non-Hodgkin's lymphoma in the U.K.

July 23, 1998

FDA grants second orphan drug designation for ImmTher

July 20, 1998

Medarex begins clinical trials of Bispecific antibody for cancer

July 20, 1998

Phase II trial of Avicine in prostate cancer announced

July 17, 1998

AltaRex initiates second phase II trial of OvaRex

July 16, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...